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FROM THE ARCHIVE
 
How Heidelberger and Avery sweetened immunology
 
In 1923, a young chemist-turned-microbiologist and his mentor made the 
startling discovery that bacterial sugars could be targeted by the immune system—
a groundbreaking finding that helped launch the field of immunochemistry.
 
In the early 1900s, decades before the in-
troduction of penicillin, pneumococcal
pneumonia was a major cause of illness
and death for which the only effective
treatment was the injection of anti-
pneumococcal  antisera. In 1917, mi-
crobiologists Alphonse Dochez and Os-
wald Avery (The Rockefeller Institute)
showed that virulent pneumococcal
bacteria released a “soluble specific sub-
stance,” that fell out of solution when in-
cubated with type-specific antisera (1).
 
All about nitrogen
 
Avery and Dochez’s initial character-
ization of this pneumococcal substance
showed that it was resistant to both
heat and trypsin—features unbefitting
most proteins—but that it did contain
nitrogen, a component of proteins. But
its true nature was not revealed until
1923, when Michael Heidelberger—
then in the chemistry department syn-
thesizing drugs against poliomyelitis
and African sleeping sickness—teamed
up with Avery.
The more they purified the reactive
substance the less nitrogen it contained.
When it was virtually nitrogen-free,
recalled Heidelberger in a 1979 article,
Avery ventured a guess: “Could it be a
carbohydrate?” (2). Chemical analysis
confirmed its sugary character, and
subsequent studies of other pneumo-
coccal serotypes revealed that each bac-
terial capsule had a distinct polysaccha-
ride signature. It was this signature that
dictated the serological specificity of
the organism. The duo published these
findings in two articles in the
 
 Journal of
Experimental Medicine
 
 (3, 4).
Their results were met with con-
siderable skepticism, as it was then
thought that only proteins could incite
a specific immune response. “Nobody
believed it,” says Emil Gotschlich
(Rockefeller University), whose later
work on polysaccharide-based vac-
cines stemmed in large part from
Heidelberger and Avery’s discoveries.
“It took them a lot of effort to con-
vince people that the polysaccharide
was the immunoreactive component.”
 
Antibodies solidified
 
Heidelberger and Avery’s discovery
came at a time when antibodies were re-
garded—by those who believed they ex-
isted at all—as mysterious substances that
floated around in serum. “It appeared to
me that there was a crying need to deter-
mine the true nature of antibodies,”
wrote Heidelberger in 1979, “and that
until this was done there could be no
end to the polemics and uncertainties
that were plaguing immunology” (2).
Heidelberger later purified the antibodies
from his precipitin reactions and showed
that they themselves were proteins. As a
result, says friend and colleague Victor
Nussenzweig (New York University),
“there were no more mystical ideas
about what antibodies were.”
Heidelberger and his postdoctoral
fellow Forrest Kendall later quantitated
the precipitin reaction (5), bringing
much-needed mathematics to the study
of antibody–antigen interactions and
lifting antibodies even further out of
the realm of the mysterious (see the
next “From the Archive”).
 
Renaissance man
 
Heidelberger’s contributions to science
were not limited to his data. He
counted among his achievements the
invention of the refrigerated centri-
fuge—an invention borne of compas-
sion for his laboratory assistant, who was
inflicted with recurrent colds due to fre-
quent trips to the cold room to centri-
fuge heat-sensitive materials. Heidel-
berger asked the centrifuge company to
build a machine with an insulated brine
coil around it. He then attached the
centrifuge to the hospital’s circulating
brine supply, which was used to cool
the refrigerators and cold rooms. His
profit for his (deliberately unpatented)
invention was a mere 50 dollars—his fee
for writing the first users’ manual (2).
But it was his science that won
Heidelberger recognition. His early
work with Avery laid the foundation for
the development of the polysaccharide-
based vaccines against pneumonia and
meningitis that are still administered
today (6, 7, 8). Their collaboration also
allowed Avery, Colin MacLeod, and
Maclyn McCarty to use the changing
sugar coat as a marker of genetic trans-
formation, and thus to identify DNA as
the genetic material (9).
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